ICU Medical financials
$163.44−0.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $551.7M | $530.2M | $540.7M | $537.0M | $548.9M | $604.7M | $629.8M | $589.1M | $596.5M | $566.7M | $587.9M | $553.3M |
| Gross profit | $235.1M | $206.2M | $203.0M | $200.9M | $208.1M | $210.1M | $227.3M | $204.9M | $207.4M | $185.2M | $171.6M | $183.9M |
| Gross margin | 42.6% | 38.9% | 37.5% | 37.4% | 37.9% | 34.7% | 36.1% | 34.8% | 34.8% | 32.7% | 29.2% | 33.2% |
| Operating income | $39.1M | $13.6M | $5.6M | $13.7M | $10.6M | $12.9M | $37.7M | $8.2M | $7.7M | -$10.7M | -$12.2M | $22.9M |
| Net income | $19.1M | $30.1M | -$15.7M | -$3.4M | $35.3M | -$15.5M | -$23.8M | -$33.0M | -$21.4M | -$39.5M | -$17.1M | $7.2M |
| Net margin | 3.5% | 5.7% | −2.9% | −0.6% | 6.4% | −2.6% | −3.8% | −5.6% | −3.6% | −7.0% | −2.9% | 1.3% |
| Diluted EPS | $0.76 | $1.20 | $-0.61 | $-0.14 | $1.43 | $-0.63 | $-0.97 | $-1.35 | $-0.88 | $-1.63 | $-0.72 | $0.30 |
| EBITDA | $110.0M | $80.4M | $76.9M | $77.7M | $76.5M | $79.0M | $100.5M | $80.7M | $80.1M | $61.3M | -$5.4M | $72.8M |
| Operating cash flow | $80.2M | $38.9M | $60.6M | $56.7M | $11.2M | $51.3M | $40.2M | $36.1M | $82.0M | $45.8M | $107.5M | $38.5M |
| Free cash flow | $61.6M | $27.6M | $36.0M | $27.6M | -$8.5M | $36.7M | $16.1M | $16.2M | $62.5M | $29.9M | $77.6M | $17.0M |
| Diluted shares | 25.0M | 25.2M | 25.7M | 24.7M | 24.7M | 24.5M | 24.5M | 24.4M | 24.4M | 24.2M | 23.9M | 24.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $298.3M | $288.3M | $308.0M | $299.7M | $300.0M | $289.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $1.23B | $1.28B | $1.28B | $1.31B | $1.34B | $1.54B |
| Total assets | $3.97B | $4.01B | $4.05B | $4.10B | $4.11B | $4.18B |
| Total liabilities | $1.82B | $1.90B | $1.93B | $1.98B | $1.99B | $2.20B |
| Shareholders' equity | $2.15B | $2.11B | $2.12B | $2.13B | $2.12B | $1.99B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology